Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy

Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD) of comb...

Full description

Bibliographic Details
Main Authors:	Loke, J, Metzner, M, Boucher, R, Jackson, A, Hopkins, L, Pavlu, J, Tholouli, E, Drummond, M, Peniket, A, Bishop, R, Fox, S, Vyas, P, Craddock, C
Format:	Journal article
Language:	English
Published:	British Society for Haematology 2021

Similar Items

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
by: Leiming Xia, et al.
Published: (2023-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy
by: Symeonidou, V, et al.
Published: (2022)

5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.
by: Craddock, C, et al.
Published: (2008)

Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
by: Vasiliki Symeonidou, et al.
Published: (2022-08-01)

5 ' AZACITIDINE IN COMBINATION WITH VALPROIC ACID INDUCES COMPLETE REMISSIONS IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA BUT DOES NOT ERADICATE CLONAL LEUKAEMIC STEM/PROGENITOR CELLS
by: Craddock, C, et al.
Published: (2009)

P550: A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHANCE-3)
by: N. G. Daver, et al.
Published: (2022-06-01)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
by: Louise Laloi, et al.
Published: (2023-03-01)

FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
by: Ai Asai-Nishishita, et al.
Published: (2023-09-01)

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.
by: M. Kalac, et al.
Published: (2022-06-01)

A phase 3, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia ineligible for intensive chemotherapy (ENHANCE-3)
by: Daver, N, et al.
Published: (2022)

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
by: Thomas Pabst, et al.
Published: (2023-02-01)

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
by: N. G. Daver, et al.
Published: (2022-06-01)

Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
by: Satoshi Yamasaki, et al.
Published: (2024-05-01)

Clonal structures of leukaemia stem cell populations in myeloid blast phase chronic myeloid leukaemia
by: Karamitros, D, et al.
Published: (2016)

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia
by: Justin Loke, et al.
Published: (2021-04-01)

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
by: Craddock, C, et al.
Published: (2017)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
by: Goodyear, O, et al.
Published: (2012)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
by: John F. Seymour, et al.
Published: (2017-12-01)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
by: DiNardo, CD, et al.
Published: (2021)

PHASE 3B STUDY DESIGN: COMPARING TREATMENT PREFERENCE BETWEEN ORAL DECITABINE/CEDAZURIDINE AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME, LOW-BLAST ACUTE MYELOID LEUKAEMIA, OR CHRONIC MYELOMONOCYTIC LEUKAEMIA
by: A. Enjeti, et al.
Published: (2024-01-01)

Romidepsin in the treatment of cutaneous T-cell lymphoma
by: Jain S, et al.
Published: (2011-04-01)

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
by: Lisa Pleyer, et al.
Published: (2016-04-01)

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)
by: Sternberg, A, et al.
Published: (2022)

Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia
by: Craddock, C, et al.
Published: (2020)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
by: Craddock, C, et al.
Published: (2013)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
by: Craddock, C, et al.
Published: (2013)

Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
by: Craddock, C, et al.
Published: (2017)

INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
by: Goodyear, O, et al.
Published: (2010)

Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
by: Craddock, C, et al.
Published: (2016)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
by: Bin-Ru Wang, et al.
Published: (2021-12-01)

Peripheral T cell lymphoma: clinical utility of romidepsin
by: Sawey K, et al.
Published: (2012-06-01)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
by: Adam J. Kleinman, et al.
Published: (2020-12-01)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
by: Fianchi Luana, et al.
Published: (2012-08-01)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
by: Guillaume Richard-Carpentier, et al.
Published: (2019-10-01)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
by: H. Dohner, et al.
Published: (2022-06-01)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
by: Ole S Søgaard, et al.
Published: (2015-09-01)

Analysis of GATA-1 mutations in chronic myeloid leukaemia.
by: Halsey, C, et al.
Published: (2006)

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia
by: Craddock, C, et al.
Published: (2011)